- Report
- September 2024
- 87 Pages
India
From €3249EUR$3,500USD£2,712GBP
- Report
- July 2025
- 188 Pages
Global
From €4177EUR$4,500USD£3,487GBP
- Report
- November 2023
- 77 Pages
United States
From €3249EUR$3,500USD£2,712GBP
- Report
- October 2024
- 200 Pages
Global
From €3481EUR$3,750USD£2,906GBP
- Report
- October 2025
- 160 Pages
Global
From €2933EUR$3,160USD£2,449GBP
€3666EUR$3,950USD£3,061GBP
- Report
- October 2023
- 130 Pages
Global
From €3500EUR$4,039USD£3,024GBP
The Oncology NGS market is a subset of the biotechnology industry that focuses on the development of technologies and products related to the diagnosis and treatment of cancer. This includes the use of next-generation sequencing (NGS) to identify genetic mutations in cancer cells, as well as the development of targeted therapies and immunotherapies to treat cancer. NGS is a powerful tool for cancer research, as it can provide a comprehensive view of the genetic makeup of a tumor, allowing for more accurate diagnosis and treatment.
The Oncology NGS market is highly competitive, with a number of companies offering products and services related to cancer diagnosis and treatment. These include Illumina, Thermo Fisher Scientific, BGI, Agilent Technologies, and Qiagen. Additionally, there are a number of smaller companies that specialize in specific areas of oncology NGS, such as bioinformatics, data analysis, and drug development. Show Less Read more
